Animal models of the cancer anorexia-cachexia syndrome

被引:72
|
作者
Bennani-Baiti, Nabila [1 ]
Walsh, Declan [1 ,2 ]
机构
[1] Cleveland Clin, Taussig Canc Ctr, Sect Palliat Med & Suppport Oncol, Cleveland, OH 44106 USA
[2] Cleveland Clin, Taussig Canc Ctr, Harry R Horvitz Ctr Palliat Med, Cleveland, OH 44106 USA
关键词
Animal models; Cancer cachexia; Anorexia; Wasting; TUMOR-BEARING RATS; PROTEOLYSIS-INDUCING FACTOR; NECROSIS-FACTOR-ALPHA; LIPID-MOBILIZING FACTOR; GROWTH-FACTOR-I; WEIGHT-LOSS; SKELETAL-MUSCLE; THERAPEUTIC STRATEGIES; PROTEIN-TURNOVER; MESSENGER-RNA;
D O I
10.1007/s00520-010-0972-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and aims Cancer cachexia, a complex wasting syndrome, is common in palliative medicine. Animal models expand our understanding of its mechanisms. A review of cancer cachexia and anorexia animal models will help investigators make an informed choice of the study model. Results and discussion Cancer-anorexia cachexia animal models are numerous. No one is ideal. The choice should depend on the research question. To investigate cancer-anorexia cachexia independent of pro-inflammatory cytokine effects, the MAC16 ADK and XK1 are useful. MAC16 ADK helps study the host's tumor metabolic effects, independent of any anorexia or inflammation. XK1 is both anorectic and cachectic, but data about it is limited. All other models induce a host inflammatory response. The Walker 256 ADK and MCG 101 are best avoided due to excessive tumor growth. Since individual models do not address all aspects of the syndrome, use of a combination seems wise. Suggested combinations: MAC16-ADK (non-inflammatory and non-anorectic) with YAH-130 (inflammatory, anorectic, and cachectic), Lewis lung carcinoma (slow onset anorexia) or prostate adenocarcinoma (inflammatory, anorectic but not cachectic) with YAH-130.
引用
收藏
页码:1451 / 1463
页数:13
相关论文
共 50 条
  • [21] ANOREXIA-CACHEXIA SYNDROME - NEW HYPOTHESIS
    THEOLOGIDES, A
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1974, 230 (MAR18) : 14 - 22
  • [22] Neural control of the anorexia-cachexia syndrome
    Laviano, Alessandro
    Inui, Akio
    Marks, Daniel L.
    Meguid, Michael M.
    Pichard, Claude
    Rossi Fanelli, Filippo
    Seelaender, Marilia
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2008, 295 (05): : E1000 - E1008
  • [23] Cancer anorexia-cachexia syndrome - Psychological effect on the patient and family
    McClement, S
    JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING, 2005, 32 (04) : 264 - 268
  • [24] Integrative role of neuropeptides and cytokines in cancer anorexia-cachexia syndrome
    Patra, Surajeet K.
    Arora, Sarika
    CLINICA CHIMICA ACTA, 2012, 413 (13-14) : 1025 - 1034
  • [25] Nutrition support and pharmacotherapy in cancer patients with anorexia-cachexia syndrome
    Snegovoy, Anton
    Manzuk, Ludmila
    Kanagavel, Dheepak
    Blokhin, N. N.
    ANNALS OF ONCOLOGY, 2007, 18 : 195 - 195
  • [26] Cancer anorexia-cachexia syndrome: Current issues in research and management
    Inui, A
    CA-A CANCER JOURNAL FOR CLINICIANS, 2002, 52 (02) : 72 - 91
  • [27] SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023)
    Rivas, Ainara Soria
    Alvarez, Yolanda Escobar
    Cordellat, Ana Blasco
    Tarruella, Margarita Majem
    Mata, Kevin Molina
    Sanchez, M. del Mar Munoz
    de la Camara, Marta Motilla
    Poves, Marta Zafra
    Zambrano, Carmen Beato
    Gutierrez, Luis Cabezon
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (11): : 2866 - 2876
  • [28] Pharmacological therapy of cancer anorexia-cachexia
    Cardona, D.
    NUTRICION HOSPITALARIA, 2006, 21 : 17 - 26
  • [29] BRAIN TRYPTOPHAN AND THE NEOPLASTIC ANOREXIA-CACHEXIA SYNDROME
    KRAUSE, R
    JAMES, JH
    ZIPARO, V
    FISCHER, JE
    CANCER, 1979, 44 (03) : 1003 - 1008
  • [30] Assessing and managing the symptoms associated with the anorexia-cachexia syndrome in cancer patients
    Andrew, I.
    Holden, K.
    Hawkins, C.
    PHARMACY WORLD & SCIENCE, 2008, 30 (04): : 420 - 420